Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia

Histone deacetylase inhibitors (HDACi) are established anticancer drugs, especially in hematological cancers. This study aimed to design, synthesize, and evaluate a set of HDACi featuring a pentyloxyamide connecting unit linker region and substituted phenylthiazole cap groups. A structural optimizat...

Full description

Saved in:

Bibliographic Details
Main Author:	Fabian Fischer (1519975) (author)
Other Authors:	Julian Schliehe-Diecks (9328092) (author), Jia-Wey Tu (20347459) (author), Tanja Gangnus (18453288) (author), Yu Lin Ho (20347462) (author), Mara Hebeis (20347465) (author), Leandro A. Alves Avelar (11918921) (author), Katerina Scharov (20347468) (author), Titus Watrin (20347471) (author), Marie Kemkes (20347474) (author), Pawel Stachura (20347477) (author), Katharina Daugs (20347480) (author), Lukas Biermann (19786133) (author), Josefa Kremeyer (20347483) (author), Nadine Horstick (20347486) (author), Ingrid Span (1321215) (author), Aleksandra A. Pandyra (8444013) (author), Arndt Borkhardt (2891) (author), Holger Gohlke (525601) (author), Matthias U. Kassack (534448) (author), Bjoern B. Burckhardt (6930629) (author), Sanil Bhatia (5945495) (author), Thomas Kurz (1648405) (author)
Published:	2024
Subjects:	Biochemistry Molecular Biology Pharmacology Cancer Hematology Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified nanomolar inhibitory activity intermediate microsomal stability excellent plasma stability established anticancer drugs displayed synergistic activity catalytic domain 2 iib hdac inhibitors histone deacetylase class 4m </ b 4d </ b several approved hdaci iib enzymes based class therapeutic potential study aimed ray crystallography promising profile novel pentyloxyamide hematological cancers hdaci featuring effectively inhibited demonstrated comparable danio rerio binding modes
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia

Similar Items